StableStock

South Korean stocks are under heavy selling pressure today. 📉 The KOSPI plunged over 7% intraday, with SK hynix (KRX: 000660) down nearly 9% and Samsung Electronics (KRX: 005930) falling almost 8%. Concerns over intensifying memory competition and weakness in global https://t.… Read more

AI is reshaping healthcare, from drug discovery to diagnostics and personalized care. 🧬 Who stands to benefit? We mapped out 6 key segments and the companies to watch across U.S. and Hong Kong markets. From $TEM and $RXRX to $ISRG and $HIMS, explore the AI Healthcare https://… Read more

Inflation, earnings, and AI take center stage this week 👀 U.S. CPI and PPI will put Fed rate expectations to the test, while Wall Street kicks off another earnings season. $JPM, $GS and other major banks report, followed by $ASML and $TSM — a crucial check on the AI capex http… Read more

What a night in Singapore! 🇸🇬🥂 Great conversations, familiar faces, and new connections. Thanks to everyone who joined us at After the Bell. Until next time https://t.co/zpjylVEbnz

Three key developments for $HAE as Haemonetics expands its plasma and medical technology businesses. • Plasma expansion: CSL Plasma plans to deploy Haemonetics’ NexSys PCS systems with Persona PLUS technology across all its existing U.S. collection centers by the end of 2027. ht… Read more

Xiaomi shares surged around 6% in Hong Kong today. 🚗 $XIACY $XIACF | HKEX: 1810 Xiaomi's new Pengcheng N70 and N90 SUVs secured over 70,000 locked-in orders in their first 30 days, while total vehicle deliveries surpassed 40,000 in September. With its EV lineup expanding into… Read more

AI optical stocks are under pressure ahead of the open. 📉 $COHR fell over 3% in premarket trading, while $LITE and $CRDO dropped more than 2%. $MRVL and $GLW also moved lower. Oil prices and Treasury yields are climbing, adding pressure to high-growth AI infrastructure names.

Nike’s turnaround remains in focus after its latest earnings. $NKE reported Q1 revenue of $11.2B, down 4% YoY, while Greater China revenue fell 22%. EPS beat expectations and gross margin improved, but the company now expects full-year revenue to decline by a high-single-digit h… Read more

Three catalysts are lining up for $UTHR. • Patent win: A U.S. court ruled that Liquidia’s Yutrepia infringes key UTHR patent claims covering inhaled treprostinil for PH-ILD. • Tyvaso expansion: The FDA has accepted its application for nebulized Tyvaso in IPF. If approved, it

$MU reported Q4 revenue of $54.2B and an 87% gross margin, both above expectations, while shares were little changed after hours. Management expects memory supply-demand conditions to tighten further in 2027 and 2028. With AI demand continuing to grow, memory pricing and supply